- Genedata is chosen by BioCopy to streamline development of multi-specific biotherapeutics.
- BioCopy integrates Genedata’s platforms to manage and analyze complex R&D data.
- Genedata Biologics and Genedata Screener® are utilized for antibody engineering workflows.
- BioCopy’s AI-driven platform evaluates extensive data for effective drug candidate development.
- The partnership aims to expedite the creation of advanced cancer therapies.
Main AI News:
Genedata, a leading provider of software solutions for biopharmaceutical R&D, has been selected by BioCopy, a pioneering biotech firm integrating AI with automated protein engineering to advance cancer therapies. BioCopy aims to streamline the discovery and development of next-generation multi-specific biotherapeutics with Genedata’s advanced platforms.
Jörg Birkenfeld, Ph.D., CSO of BioCopy, highlighted, “We integrated Genedata as our data backbone to unify project and group information on a central platform, expediting the development of cancer drugs. Our automated lab generates vast, complex data that Genedata structures into actionable insights, crucial for speeding up our research and enabling data-driven drug design.”
BioCopy’s AI-powered, automated platform supports the creation of effective and safe multi-specific biotherapeutics. Through their proprietary ValidaTe technology, BioCopy conducts extensive analyses of cancer cell marker interactions with potential therapeutics. The lab’s capacity to synthesize various molecular components into a single candidate and evaluate up to 25,000 novel candidates simultaneously accelerates biotherapeutic development.
The complexity of BioCopy’s R&D data has driven their choice of Genedata Biologics® and Genedata Screener® to optimize sophisticated multi-specific antibody engineering. Genedata Biologics aids in designing, registering, tracking, and analyzing candidate molecules, while ensuring complete data traceability and integration with BioCopy’s lab instruments and IT systems.
Othmar Pfannes, Ph.D., CEO of Genedata, commented, “We are thrilled to support BioCopy’s AI-driven R&D efforts, enhancing their efficiency and expediting the delivery of innovative therapeutics. Genedata remains committed to advancing our platform to support AI and ML-based drug discovery.”
Conclusion:
BioCopy’s selection of Genedata highlights a significant shift in the biopharmaceutical market towards leveraging AI and advanced data management to accelerate drug development. By incorporating Genedata’s sophisticated platforms, BioCopy aims to enhance the efficiency of their R&D processes, which could set a new standard for how biotechs approach multi-specific antibody development. This partnership underscores the growing importance of integrating AI-driven solutions to handle complex data and drive innovation, potentially leading to faster market entry for cutting-edge therapeutics and increased competition among biopharmaceutical companies to adopt similar technologies.
